KYNB
Kyntra Bio, Inc. NASDAQ Listed Nov 14, 2014$7.19
Mkt Cap $29.1M
52w Low $4.85
30.2% of range
52w High $12.60
50d MA $7.05
200d MA $8.94
P/E (TTM)
0.2x
EV/EBITDA
0.3x
P/B
6.4x
Debt/Equity
0.0x
ROE
-610.7%
P/FCF
-7.4x
RSI (14)
—
ATR (14)
—
Beta
0.90
50d MA
$7.05
200d MA
$8.94
Avg Volume
30.8K
Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.
350 Bay Street · San Francisco, CA 94133 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | AMC | -3.89 | -3.61 | +7.2% | 7.00 | -1.4% | +5.3% | +0.7% | +4.3% | +1.9% | +0.9% | — |
| Nov 10, 2025 | AMC | -4.01 | -1.61 | +59.9% | 11.00 | +0.1% | -9.6% | -17.0% | -17.5% | -21.0% | -20.9% | — |
| Aug 11, 2025 | AMC | -2.25 | -3.38 | -50.2% | 8.37 | +9.3% | +10.5% | +18.0% | +13.3% | +13.4% | +35.0% | — |
| May 12, 2025 | AMC | 0.75 | -4.00 | -633.3% | 7.64 | +4.7% | -2.1% | -1.8% | -1.2% | +0.1% | +2.6% | — |
| Mar 17, 2025 | AMC | -0.08 | -0.08 | +0.0% | 11.13 | -15.5% | -21.8% | -19.7% | -24.4% | -29.2% | -17.1% | — |
| Nov 12, 2024 | AMC | -0.38 | -0.17 | +55.3% | 9.66 | +5.0% | -14.0% | -4.2% | -13.4% | -12.7% | -9.4% | — |
| Aug 6, 2024 | AMC | -0.26 | -0.16 | +38.5% | 11.00 | +11.4% | +4.5% | +0.2% | -7.0% | -12.5% | -11.4% | — |
| May 6, 2024 | AMC | -0.31 | -0.33 | -6.5% | 29.00 | +12.9% | +18.1% | -2.6% | +5.2% | +0.0% | +4.3% | — |
| Feb 26, 2024 | AMC | -0.42 | -0.57 | -35.7% | 46.25 | -13.0% | +14.6% | +7.6% | -7.6% | -1.1% | +7.0% | — |
| Nov 6, 2023 | AMC | -0.68 | -0.52 | +23.5% | 13.98 | +14.4% | -1.2% | -14.9% | -30.3% | -32.0% | -25.7% | — |
| Aug 7, 2023 | AMC | -0.72 | -0.65 | +9.7% | 44.25 | -6.2% | -18.6% | -22.6% | -18.6% | -24.3% | -26.6% | — |
| May 8, 2023 | AMC | -0.76 | -0.81 | -6.6% | 444.25 | -5.7% | -2.0% | +0.2% | -1.0% | -1.9% | -0.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.97 | $12.23 | +2.2% | +3.4% | +2.3% | +2.8% | +2.9% | +2.3% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.11 | $7.18 | +1.0% | +11.7% | +22.5% | +17.7% | +30.1% | +39.0% |
| Aug 7 | BofA Securities | Downgrade | Neutral → Underperform | — | $47.75 | $47.75 | +0.0% | -7.3% | -24.6% | -28.3% | -24.6% | -29.8% |
| Jun 26 | Goldman Sachs | Maintains | Sell → Sell | — | $401.25 | $79.75 | -80.1% | -83.1% | -84.4% | -84.5% | -83.6% | -83.2% |
| Jun 25 | William Blair | Downgrade | Outperform → Market Perform | — | — | — | — | — | — | — | — | — |
| Jun 25 | Stifel | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
| Jun 25 | Raymond James | Downgrade | Outperform → Market Perform | — | — | — | — | — | — | — | — | — |
| Jun 25 | BofA Securities | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Jun 1 | Stifel | Upgrade | Hold → Buy | — | $431.25 | $432.75 | +0.3% | +0.4% | +3.7% | +11.2% | +8.5% | -0.7% |
| Feb 27 | Cowen & Co. | Maintains | Market Perform → Market Perform | — | $555.25 | $563.25 | +1.4% | +1.4% | -0.0% | -0.8% | +0.1% | -0.9% |
| Feb 22 | Goldman Sachs | Maintains | Sell → Sell | — | $565.00 | $571.25 | +1.1% | -0.4% | -0.7% | -1.7% | -0.4% | -1.8% |
| Feb 20 | Goldman Sachs | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Jan 30 | William Blair | Upgrade | Market Perform → Outperform | — | $543.75 | $542.50 | -0.2% | -0.7% | +8.5% | +12.1% | +14.3% | +13.0% |
| Jan 25 | Raymond James | Upgrade | Market Perform → Outperform | — | $508.25 | $504.75 | -0.7% | +1.6% | +8.8% | +7.0% | +6.2% | +16.1% |
| Jan 4 | BofA Securities | Upgrade | Neutral → Buy | — | $398.75 | $399.25 | +0.1% | +0.9% | +12.9% | +24.1% | +24.8% | +31.7% |
| Nov 7 | Goldman Sachs | Maintains | Sell → Sell | — | $406.25 | $409.25 | +0.7% | -0.6% | -12.9% | -7.0% | -0.6% | -4.6% |
| May 23 | Goldman Sachs | Maintains | Sell → Sell | — | $215.00 | $216.25 | +0.6% | +1.7% | -0.9% | +0.7% | +7.2% | +16.9% |
| Feb 28 | Goldman Sachs | Maintains | Sell → Sell | — | $363.00 | $358.75 | -1.2% | -3.1% | -6.2% | -7.8% | -9.4% | -10.6% |
| Sep 21 | Goldman Sachs | Downgrade | Neutral → Sell | — | $281.75 | $284.25 | +0.9% | -0.3% | -9.7% | -4.7% | -4.2% | -4.1% |
| Aug 19 | Raymond James | Upgrade | Underperform → Market Perform | — | $301.50 | $299.75 | -0.6% | -4.9% | +0.4% | +1.2% | +0.3% | -1.6% |
| Aug 9 | SVB Leerink | Maintains | Outperform → Outperform | — | $343.25 | $345.00 | +0.5% | +0.4% | -3.9% | -9.5% | -8.3% | -9.7% |
| Jul 15 | Stifel | Downgrade | Buy → Hold | — | $621.00 | $621.00 | +0.0% | +0.0% | -42.2% | -44.8% | -42.0% | -42.9% |
| Jul 15 | BofA Securities | Downgrade | Buy → Neutral | — | $621.00 | $621.00 | +0.0% | +0.0% | -42.2% | -44.8% | -42.0% | -42.9% |
| Apr 6 | Mizuho | Downgrade | Buy → Neutral | — | $890.75 | $883.00 | -0.9% | -2.8% | -44.6% | -47.2% | -47.9% | -44.2% |
| Apr 6 | JP Morgan | Upgrade | Underweight → Neutral | — | $890.75 | $883.00 | -0.9% | -2.8% | -44.6% | -47.2% | -47.9% | -44.2% |
| Apr 6 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $890.75 | $883.00 | -0.9% | -2.8% | -44.6% | -47.2% | -47.9% | -44.2% |
| Apr 6 | SVB Leerink | Maintains | Outperform → Outperform | — | $890.75 | $883.00 | -0.9% | -2.8% | -44.6% | -47.2% | -47.9% | -44.2% |
| Mar 30 | BofA Securities | Upgrade | Neutral → Buy | — | $775.00 | $775.00 | +0.0% | +0.4% | +12.0% | +15.1% | +14.9% | +11.7% |
| Mar 1 | Jefferies | Downgrade | Buy → Hold | — | $1250.75 | $1275.75 | +2.0% | +1.0% | -23.9% | -31.3% | -32.6% | -28.7% |
| Mar 1 | SVB Leerink | Maintains | Outperform → Outperform | — | $1250.75 | $1275.75 | +2.0% | +1.0% | -23.9% | -31.3% | -32.6% | -28.7% |
| Feb 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1204.50 | $1244.25 | +3.3% | +3.0% | +2.4% | +2.6% | +4.8% | +8.5% |
| Nov 5 | SVB Leerink | Maintains | Outperform → Outperform | — | $1046.50 | $1065.50 | +1.8% | +1.4% | -1.4% | -2.5% | -2.4% | -1.3% |
| Oct 26 | Raymond James | Maintains | Underperform → Underperform | — | $1065.00 | $1059.50 | -0.5% | -6.2% | -8.2% | -10.0% | -8.4% | -9.9% |
| Sep 7 | SVB Leerink | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Aug 6 | SVB Leerink | Maintains | Outperform → Outperform | — | $1066.25 | $1068.25 | +0.2% | -2.8% | +3.6% | +5.9% | +5.6% | +5.7% |
| May 7 | SVB Leerink | Maintains | Outperform → Outperform | — | $899.75 | $924.75 | +2.8% | +1.2% | +1.2% | +10.1% | +4.7% | +0.3% |
| May 1 | Cowen & Co. | Maintains | Market Perform → Perform | — | $922.25 | $899.25 | -2.5% | -5.2% | +0.2% | -1.6% | -2.4% | -1.3% |
| Apr 27 | BofA Securities | Maintains | Neutral → Neutral | — | $1021.50 | $1026.75 | +0.5% | -2.3% | -4.1% | -2.7% | -9.7% | -14.4% |
| Aug 25 | Mizuho | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 9 | William Blair | Downgrade | Outperform → Market Perform | — | $1160.25 | $1149.25 | -0.9% | -1.6% | -21.6% | -24.3% | -19.3% | -18.5% |
| Apr 12 | PiperJaffray | Maintains | Neutral → Neutral | — | $1318.25 | $1332.75 | +1.1% | -8.9% | -7.5% | -8.0% | -12.5% | -10.5% |
| Dec 18 | Citigroup | Upgrade | Neutral → Buy | — | $974.75 | $1027.50 | +5.4% | +1.3% | +4.5% | +8.8% | +3.2% | +4.3% |
| Oct 14 | Leerink Swann | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| May 14 | Mizuho | Upgrade | Neutral → Buy | — | $1185.00 | $1195.00 | +0.8% | +4.9% | +7.8% | +11.0% | +8.2% | +7.9% |
| Oct 5 | Mizuho | Maintains | Neutral → Neutral | — | $1502.50 | $1453.75 | -3.2% | -5.7% | -8.2% | -8.3% | -8.2% | -6.1% |
| Jul 20 | Goldman Sachs | Downgrade | Buy → Neutral | — | $867.50 | $872.50 | +0.6% | +1.6% | +0.7% | +2.4% | +1.4% | +2.3% |
| Jul 11 | Jefferies | Maintains | Buy → Buy | — | $813.75 | $826.25 | +1.5% | +2.8% | +2.5% | +3.1% | +2.9% | +7.5% |
| Feb 10 | Credit Suisse | Upgrade | Neutral → Outperform | — | $383.25 | $386.50 | +0.8% | -1.6% | +12.1% | +15.5% | +21.1% | +29.2% |
| Jan 20 | Credit Suisse | Maintains | Neutral → Neutral | — | $535.50 | $524.00 | -2.1% | +0.5% | -4.5% | -2.3% | -1.0% | -4.1% |
| Dec 4 | Citigroup | Maintains | Buy → Buy | — | $746.25 | $751.75 | +0.7% | +1.7% | -1.0% | +2.9% | -3.3% | +2.7% |
No insider trades available.
8-K
Unknown — 8-K Filing
KYNB faces delisting risk from Nasdaq's non-compliance issues, though management is pursuing remediation plans; investors should monitor quarterly progress toward regaining compliance standards.
Apr 9
8-K
Unknown — 8-K Filing
Kyntra Bio's $109.4M cash position extending runway to 2028 provides substantial time to advance FDA programs without immediate dilution, supporting stock stability for clinical-stage biotech investors.
Mar 16
8-K · 7.01
! Medium
Zura Bio Limited Class A -- 8-K 7.01: Regulation FD Disclosure
Zura Bio disclosed material information via press release on February 23, 2026, subject to Regulation FD requirements without admitting materiality determinations for investor consideration.
Feb 23
Data updated apr 25, 2026 6:18pm
· Source: massive.com